Enjoy complimentary customisation on priority with our Enterprise License!
The multiple myeloma drugs market size is forecast to increase by USD 7.94 billion at a CAGR of 6.78% between 2023 and 2028. In the realm of oncology therapeutics, the multiple myeloma therapeutics segment continues to evolve, driven by positive clinical data and advancements in treatment options. Multiple myeloma is a disorder characterized by the production of abnormal plasma cells, leading to a poor prognosis for patients. The market is segmented into immunomodulators, proteasome inhibitors, alkylating agents, and the emerging segment of XPO1 inhibitors. Notable developments include the FDA approval of Sarclisa (isatuximab-irfc), an anti-CD38 monoclonal antibody, expanding the armamentarium against multiple myeloma. The emergence of nanomedicine platforms and the growing popularity of complementary and alternative medicines further fuel market growth. This trend is expected to continue as researchers strive to improve patient outcomes and extend survival.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.